Hisun In-Licenses China Rights to Celsion’s Cancer Drug for $100 Million
Zhejiang Hisun Pharma has in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal that totals $100 million in upfront and milestone payments. Celsion is expected to announce results from a Phase III trial of the drug later this month. In May 2012, Celsion chose Hisun as its global manufacturer for ThermoDox. Celsion expects the deal to be worth “hundreds of million of dollars” over time in milestones and royalties, given the prevalence of liver cancer in China. More details.... Stock Symbols: (SHA: 600267) (NSDQ: CLSN) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here